Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024
Compugen (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and pioneer in computational target discovery, has announced the upcoming release of its second quarter 2024 financial results. The results will be disclosed on Tuesday, August 6, 2024, before the U.S. financial markets open. Following the release, the company's management will host a conference call and webcast at 8:30 AM ET to review the results and provide a corporate update.
Investors and interested parties can access the live conference call by dialing 1-866-744-5399 from the U.S. or +972-3-918-0644 internationally. Additionally, a live webcast will be available through Compugen's website. For those unable to attend the live event, a replay will be made available on the company's website following the webcast.
Compugen (Nasdaq: CGEN) (TASE: CGEN), un azienda di immunoterapia oncologica in fase clinica e pioniere nella scoperta di target computazionali, ha annunciato il prossimo rilascio dei suoi risultati finanziari del secondo trimestre del 2024. I risultati saranno resi noti il martedì 6 agosto 2024, prima dell'apertura dei mercati finanziari statunitensi. Dopo il rilascio, il management dell'azienda ospiterà una conference call e un webcast alle 8:30 ET per rivedere i risultati e fornire un aggiornamento aziendale.
Gli investitori e le parti interessate possono accedere alla conference call in diretta componendo il numero 1-866-744-5399 dagli Stati Uniti o +972-3-918-0644 a livello internazionale. Inoltre, sarà disponibile un webcast live attraverso il sito web di Compugen. Per coloro che non possono partecipare all'evento dal vivo, sarà messo a disposizione un replay sul sito dell'azienda dopo il webcast.
Compugen (Nasdaq: CGEN) (TASE: CGEN), una empresa de inmunoterapia oncológica en etapa clínica y pionera en el descubrimiento de objetivos computacionales, ha anunciado el próximo lanzamiento de sus resultados financieros del segundo trimestre de 2024. Los resultados se darán a conocer el martes 6 de agosto de 2024, antes de que abran los mercados financieros de EE. UU. Tras el anuncio, la dirección de la empresa realizará una llamada de conferencia y webcast a las 8:30 AM ET para revisar los resultados y proporcionar una actualización corporativa.
Los inversores y las partes interesadas pueden acceder a la llamada de conferencia en vivo marcando el 1-866-744-5399 desde EE. UU. o +972-3-918-0644 internacionalmente. Además, habrá un webcast en vivo disponible a través de la página web de Compugen. Para aquellos que no puedan asistir al evento en vivo, se proporcionará una repetición en el sitio web de la empresa después del webcast.
Compugen (Nasdaq: CGEN) (TASE: CGEN)은 임상 단계의 암 면역 치료 회사이자 컴퓨터 기반 표적 발견 분야의 선구자로서 2024년 2분기 재무 결과를 발표할 예정이라고 밝혔습니다. 결과는 2024년 8월 6일 화요일, 미국 금융 시장이 열리기 전에 공개될 것입니다. 발표 후, 회사 경영진은 결과 검토 및 기업 업데이트를 위해 동부 표준시 기준 오전 8시 30분에 전화 회의 및 웹캐스트를 주최할 예정입니다.
투자자 및 관심 있는 당사자는 미국에서 1-866-744-5399을, 국제적으로는 +972-3-918-0644를 다이얼하여 생중계 전화 회의에 접속할 수 있습니다. 또한 Compugen의 웹사이트를 통해 생중계 웹캐스트가 제공됩니다. 생중계에 참석할 수 없는 분들을 위해, 웹캐스트 이후 회사 웹사이트에서 리플레이가 제공될 것입니다.
Compugen (Nasdaq: CGEN) (TASE: CGEN), une entreprise de thérapie immunologique contre le cancer en phase clinique et pionnière dans la découverte de cibles par ordinateur, a annoncé la prochaine publication de ses résultats financiers du deuxième trimestre 2024. Les résultats seront divulgués le mardi 6 août 2024, avant l'ouverture des marchés financiers américains. À la suite de cette publication, la direction de l'entreprise organisera une conférence téléphonique et un webinaire à 8h30 ET pour examiner les résultats et fournir une mise à jour de l'entreprise.
Les investisseurs et les parties intéressées peuvent accéder à la conférence téléphonique en direct en composant le 1-866-744-5399 depuis les États-Unis ou le +972-3-918-0644 à l'international. De plus, un webinaire en direct sera disponible via le site Web de Compugen. Pour ceux qui ne peuvent pas assister à l'événement en direct, un enregistrement sera disponible sur le site de l'entreprise après le webinaire.
Compugen (Nasdaq: CGEN) (TASE: CGEN), ein Unternehmen für klinische Krebsimmuntherapie und Pionier in der rechnergestützten Zielentdeckung, hat die bevorstehende Veröffentlichung seiner Finanzergebnisse für das zweite Quartal 2024 angekündigt. Die Ergebnisse werden am Dienstag, den 6. August 2024, vor der Eröffnung der US-Finanzmärkte bekannt gegeben. Nach der Veröffentlichung wird das Management des Unternehmens eine Telefonkonferenz und einen Webcast um 8:30 Uhr ET abhalten, um die Ergebnisse zu überprüfen und ein Unternehmensupdate zu geben.
Investoren und Interessierte können die live Telefonkonferenz über 1-866-744-5399, aus den USA oder +972-3-918-0644 international erreichen. Zusätzlich wird ein Live-Webcast über die Website von Compugen verfügbar sein. Für diejenigen, die an der Live-Veranstaltung nicht teilnehmen können, wird auf der Unternehmenswebsite nach dem Webcast eine Wiederholung bereitgestellt.
- None.
- None.
HOLON,
To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link. Following the live webcast, a replay will be available on the Company's website.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, in IND enabling studies is licensed to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-release-second-quarter-2024-results-on-tuesday-august-6-2024-302203750.html
SOURCE Compugen Ltd.
FAQ
When will Compugen (CGEN) release its Q2 2024 financial results?
What time is Compugen's (CGEN) Q2 2024 earnings conference call?
How can I access Compugen's (CGEN) Q2 2024 earnings call?
Will there be a replay of Compugen's (CGEN) Q2 2024 earnings call?
